에 대한 최신 뉴스 SPDR Portfolio S&P 500 ETF (ARCA:SPLG)

SPDR Portfolio S&P 500 ETF

SPDR Series Trust SPDR Portfolio Large Cap ETF

Technology

Financial Services

Consumer Cyclical

Healthcare

Industrials

Consumer Defensive

Energy

Communication Services

Utilities

Real Estate

Basic Materials

Other

Under normal market conditions, the fund generally invests substantially all, but at least 80 percent, of its total assets in the securities comprising the index. The index is designed to measure the performance of the large-capitalization segment of the U.S. equity market.

Apple Inc

Microsoft Corp

Nvidia Corp.

Amazon.Com Inc

Meta Platforms, Inc.

Alphabet Inc.Class A

Alphabet Holding Company Inc.

Berkshire Hathaway, Inc.

Broadcom Inc

Tesla, Inc.

Wall Street

Analyst Color

Broad U.S. Equity ETFs

Markets

ETFs

IBIT

SPLG

상장지수펀드(ETF)는 2024년 역사적인 해를 맞이하며 금융 플레이북을 다시 쓰고 있다. 뱅크 오브 아메리카는 올해 ETF에 1.6조 달러의 자금이 유입되었으며, 글로벌 ETF 시장이 15.1조 달러의 운용 자산(AUM)으로 성장했다고 보고했다.

유입금 1.6조 달러로 2024년 ETF 시장 사상 최대 기록 경신: 선도 하는 7개 펀드들

fed-chart-ai

Macro Economic Events

Sector ETFs

Bonds

Econ #s

Economics

Federal Reserve

Tech

SPYV

TQQQ

VCIT

연방준비제도(연준)는 다가오는 연방공개시장위원회(FOMC) 회의에서 금리를 인하할 것으로 예상되며, 그 결정은 수요일 동부 표준시 오후 2시에 발표될 예정이다.

연준의 금리 인하 결정이 내려지기 전에 투자자들이 비밀리에 매수한 10가지 ETF

WIIM

Redwire shares are trading higher after the company announced it will advance lunar and martian manufacturing technology after receiving a NASA critical design review pass.

<ul>
<li>US$50 million from an existing equity financing agreement.</li>
<li>US$50 million secured through a new institutional commitment from a strategic funding partner.</li>
</ul>
&nbsp;

News

Treasure Global Launches $100M Digital Asset Treasury Strategy To Reinforce Digital Infrastructure And Support Launch Of AI-Powered Consumer Intelligence Platform

<ul>
<li>New 8-count bottles now available through major retail pharmacies</li>
<li>ARAKODA&#xAE; is the only weekly prophylactic therapy to provide protection against the blood and liver stages of malaria</li>
</ul>
WASHINGTON, June 04, 2025 (GLOBE NEWSWIRE) -- &nbsp;<a href="https://www.globenewswire.com/Tracker?data=vgk--PA0N21vNZZm2YUhkUU5CxfJSet2QN6inrIBdQCrG4FYbfHZekx7do7x22oI0hYcjJnEKkBpOOne8FBy_FD5lem3FD0DvJeltwqs8vSBh7jI9WZnZCUGwLasNq8MDvPjxUIHQEN_8AKTPqWYV3662fF7pmk0U9_j-vdzQ5tMXwCE4SEeZt67dhN3DxJORV241dnG7shjujI3lwFk7ih7fjMEf7aUODXc8TSPkSqp3632qN0XDNcZ0gGg956mr1kgdjaCeLrErCId83TmGqJw5fcWxD02yd7jBr_f9xF8wWuhhzYbIHTZNhf3oYJJurnjq-QlQreJ5gykvngF3Q==">60 Degrees Pharmaceuticals, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>, SXTPW))) ("60 Degrees" or the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the introduction of a new 8-count bottle format for ARAKODA&#xAE; (tafenoquine). The 8-count bottle format may be suitable for use with patients who are making shorter trips to areas of the world where malaria is endemic.
The new format expands the packaging options available to healthcare professionals who prescribe ARAKODA for the prevention of malaria and travelers taking trips of one week or less. The 8-count bottles are now available through major retail pharmacies, including Amazon Pharmacy.
For individuals traveling to endemic areas, ARAKODA tablets are indicated for the prophylaxis of malaria in patients 18 years of age and older. ARAKODA is the only weekly prophylactic therapy to provide protection against all stages of malaria.

Biotech

General

SXTP

60 Degrees Pharmaceuticals Launches New 8-Count Bottle Format Of ARAKODA

Counterpoint Research has cut growth expectations for <a href="https://www.benzinga.com/topic/smartphones" target="_blank" rel="noreferrer noopener">global smartphone shipments</a> in 2025 to 1.9% on Wednesday, down from 4.2% previously, citing Trump administration tariff-related uncertainties.
The firm also revised shipment growth from China down to near flat and expects Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Samsung Electronics (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>)&nbsp;shipments to slow as the companies pass the <a target="_blank" href="https://www.counterpointresearch.com/report/market-monitor-smartphone-brand-shipment-analysis-by-model-q1-2025" rel="noreferrer noopener">cost burden on</a> consumers.
President Trump announced a series of tariffs on its trading partners on April 2 to encourage manufacturing in the U.S.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/global/25/04/44796659/apple-tops-global-smartphone-sales-with-19-share-boosted-by-iphone-16e-emerging-market-growth" rel="noreferrer noopener">Apple Tops Global Smartphone Sales With 19% Share, Boosted By iPhone 16e, Emerging Market Growth</a>
On May 12, Beijing and Washington&nbsp;<a target="_blank" href="https://www.benzinga.com/government/regulations/25/05/45676270/chinese-stocks-soar-as-us-court-blocks-trump-tariffs" rel="noreferrer noopener">agreed to lower&nbsp;tariffs</a> on each other's products, temporarily offering relief to the stock market. The deal reduced U.S. levies of 145% on most Chinese imports to 30%, while China's 125% duties on U.S. goods will drop to 10% for 90 days.
Last week, International Data Corporation (IDC) in its research report cut the 2025 <a href="https://www.benzinga.com/news/25/05/45708416/apple-iphone-shipment-could-decline-in-2025-as-tariff-competition-play-spoil-sport-idc" target="_blank" rel="noreferrer noopener">global smartphone shipment</a> growth outlook to 0.6% from 2.3%.
IDC expects China smartphone shipments to grow by 3% in 2025, driven by government subsidies.
In contrast,&nbsp;Apple&nbsp;is forecast to decline 1.9% in 2025 due to ongoing competition from&nbsp;Huawei, the overall economic slowdown, and the lack of subsidies for most of its models.
IDC expects the U.S. smartphone shipment to grow 1.9% in 2025, down from 3.3% in 2017, due to increased uncertainty and tariff-related price increases.
Meanwhile, Deepwater Research&#8217;s Gene Munster estimated that Apple has <a href="https://www.benzinga.com/markets/tech/25/06/45764870/apple-has-at-least-two-years-before-losing-customers-despite-its-several-ai-missteps-says-gene-munster-heres-why" target="_blank" rel="noreferrer noopener">about two years</a> to perfect its AI strategy, but it will require increased investments.
The AI features of smartphones are the<a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44613270/apple-set-for-strong-iphone-upgrade-cycle-driven-by-ai-analyst-says" rel="noreferrer noopener"> key deciding factor</a> determining their prospects.
<h2 class="wp-block-heading">Apple Stock Prediction For 2025</h2>
Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.
Shares of Apple have an average 1-year price target of $238.79, representing an expected upside of 17.47%.
Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. 3 analysts have bearish recommendations on Apple, while 21 analysts have bullish ratings. The street high price target from Wedbush is $325.0, while the street low from Jefferies is $167.88.
APPL&nbsp;Price Action:&nbsp;Apple stock is down 0.50% to $202.26 premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45756083/which-internet-software-stocks-is-jp-morgan-bullish-on" target="_blank" rel="noreferrer noopener">Which Internet Software Stocks Is JP Morgan Bullish On?</a></li>
</ul>
Image by Wongsakorn 2468 via Shutterstock

Trading Ideas

AAPL

SSNLF

Tariffs, AI And Trade War: Apple's Smartphone Growth To Take A Hit, Experts Say

FUFU

BitFuFu shares are trading higher after the company provided monthly Bitcoin holdings and production updates for May.

Swedish biopharmaceutical company Camurus AB entered a collaboration and license agreement with Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) on Tuesday.
Camurus granted Eli Lilly exclusive, worldwide rights to research, develop, manufacture, and commercialize <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">long-acting incretin</a> products for cardiometabolic health based on Camurus&#8217; FluidCrystal technology.
The agreement <a target="_blank" href="https://www.camurus.com/media/press-releases/2025/camurus-and-lilly-enter-collaboration-and-license-agreement-for-long-acting-fluidcrystal-incretins/" rel="noreferrer noopener">comprises</a> up to four Lilly proprietary drug compounds, selected from dual GIP and GLP-1 receptor agonists, triple GIP, glucagon, and GLP-1 receptor agonists, and an option to include amylin receptor agonists.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45341500/eli-lillys-zepbound-shows-superior-weight-loss-over-novo-nordisks-wegovy-in-head-to-head-trial" rel="noreferrer noopener">Eli Lilly&#8217;s Zepbound Shows Superior Weight Loss Over Novo Nordisk&#8217;s Wegovy In Head-To-Head Trial</a>
Camurus' FluidCrystal technology is designed to deliver therapeutic levels of drug substance over extended periods – from days to months – with a single injection using a prefilled syringe or autoinjector pen.
Upon contact with bodily fluids in the tissue, the lipid solution transforms into a liquid crystalline gel that quickly and effectively encapsulates the active ingredient. The drug is slowly released as the liquid crystalline matrix gradually degrades in the tissue.
The technology is commercially and regulatory validated by market approvals and product sales in Europe, the US, and Australia.
In return for granting Lilly the license to use the FluidCrystal technology for the selected incretin drug compounds for cardiometabolic health, Camurus is eligible to receive up to&nbsp;$290 million&nbsp;in upfront, development, and regulatory milestone payments, $580 million in sales-based milestone payments, and tiered mid-single-digit royalties on global net product sales.
In May, Eli Lilly agreed to acquire&nbsp;SiteOne Therapeutics, Inc., a private biotechnology company developing small-molecule inhibitors of sodium channels to treat pain and other neuronal&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45629147/breaking-the-pain-barrier-lillys-acquisition-of-siteone-aims-for-opioid-alternatives" rel="noreferrer noopener">hyperexcitability disorders</a>.
The transaction includes STC-004, a Phase 2 ready Nav1.8 inhibitor being&nbsp;studied for pain.
STC-004 may represent a next-generation, non-opioid treatment for patients suffering from chronic pain.
In May, Eli Lilly entered into a strategic global research collaboration and licensing agreement with Rznomics Inc., a South Korea-based biopharmaceutical company specializing <a href="https://www.benzinga.com/25/05/45450675/eli-lilly-collaborates-with-south-korea-based-rznomics-for-rna-editing-therapies-for-hearing-loss-treatment-in-over-13-billion-pact" target="_blank" rel="noopener">in RNA-based therapeutics</a>.
The agreement focuses on developing and commercializing RNA-editing therapies using Rznomics&#8217; proprietary trans-splicing ribozyme platform.
The collaboration&nbsp;<a target="_blank" href="https://www.prnewswire.com/news-releases/rznomics-enters-global-licensing-agreement-with-eli-lilly-for-rna-editing-therapeutics-302456852.html?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">focuses</a>&nbsp;on discovering and developing RNA-editing therapeutics for sensorineural hearing loss. Rznomics will conduct early-stage research according to the jointly approved research plans, while Lilly will assume responsibility for further development and commercialization.
Price Action: At the last check on Wednesday, LLY stock was up 0.40% at $753.80 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/06/45767454/autoliv-boosts-shareholder-returns-with-21-dividend-hike-new-2-5-billion-buyback-program" target="_blank" rel="noreferrer noopener">Autoliv Boosts Shareholder Returns With 21% Dividend Hike, New $2.5 Billion Buyback Program</a></li>
</ul>
Photo: Shutterstock

Health Care

Mounjaro Maker Eli Lilly Taps Swedish Firm Camurus To Target Long-Acting Obesity Market In $870-Million Deal

Telsey Advisory Group analyst Dana Telsey maintains Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) with a Market Perform and maintains $24 price target.

Price Target

Analyst Ratings

VSCO

Telsey Advisory Group Maintains Market Perform on Victoria's Secret, Maintains $24 Price Target

REVG

REV Group shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 sales guidance.

Competitive statewide RFP win provides a platform for efficient expansion within the state
TEL AVIV, Israel, June 4, 2025 /PRNewswire/ -- SuperCom (NASDAQ:&nbsp;SPCB),&nbsp;a global provider of secure solutions for the e-Government, IoT, and Cybersecurity sectors, announced today that it has been awarded a statewide technology procurement contract by the North Carolina Sheriff's Association, emerging as the only new electronic monitoring technology provider selected through this competitive RFP. This contract serves as a procurement vehicle to allow all counties in North Carolina to contract directly with SuperCom on preset terms, most of the time without an additional RFP process. This strategic win is another testament to the Company's rapid expansion across the North American public safety market.

Contracts

SPCB

SuperCom Wins Statewide Technology Procurement Contract With North Carolina Sheriff's Association As Sole New Electronic Monitoring Provider

YEXT

Yext shares are trading higher after the company raised its FY26 adjusted EPS guidance above estimates. Also, Needham reiterated a Buy rating on the stock.

Telsey Advisory Group analyst Dana Telsey maintains Steven Madden (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) with a Market Perform and maintains $24 price target.

SHOO

Telsey Advisory Group Maintains Market Perform on Steven Madden, Maintains $24 Price Target

JFIN

Jiayin Group shares are trading higher after the company reported a year-over-year increase in its Q1 financial results.

Keybanc analyst Bradley Thomas reiterates Ollie's Bargain Outlet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) with a Overweight and maintains $135 price target.

Reiteration

OLLI

Keybanc Reiterates Overweight on Ollie's Bargain Outlet, Maintains $135 Price Target

Thor Industries shares are trading higher after the company reported better-than-expected Q3 financial results.

Telsey Advisory Group analyst Joseph Feldman maintains Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) with a Market Perform and maintains $95 price target.

DLTR

Telsey Advisory Group Maintains Market Perform on Dollar Tree, Maintains $95 Price Target

Keybanc analyst Bradley Thomas reiterates Dollar General (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) from Sector Weight to Sector Weight.

Keybanc Reiterates Sector Weight on Dollar Generalto Sector Weight

MRUS

Merus shares are trading lower following its $300 million public offering announcement.

LITE

Lumentum Holdings shares are trading higher after the company raised its Q4 guidance. Additionally, Rosenblatt raised its price target on the stock from $94 to $105.

UBS analyst Karl Keirstead upgrades Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) from Neutral to Buy and raises the price target from $210 to $265.

Upgrades

SNOW

UBS Upgrades Snowflake to Buy, Raises Price Target to $265

ASAN

Asana shares are trading lower after the company issued FY26 guidance below estimates.

상장지수펀드(ETF)는 2024년 역사적인 <a href="https://www.benzinga.com/etfs" target="_blank" rel="noopener" data-google-interstitial="false">해를 맞이하며</a> 금융 플레이북을 다시 쓰고 있다.
뱅크 오브 아메리카는 올해 ETF에 1.6조 달러의 자금이 유입되었으며, 글로벌 ETF 시장이 15.1조 달러의 운용 자산(AUM)으로 성장했다고 보고했다.
또한, ETF 출시 수는 2024년에 1,485개로 사상 최고치를 기록했으며, 기관 소유가 계속해서 증가하여 ETF가 현대 투자 전략의 초석으로 자리 잡게 되었다.
ETF 생태계가 어떻게 진화하고 있는지, 그리고 그것이 왜 중요한지 살펴보겠다.
<h2 class="wp-block-heading">ETF 성장의 기록적인 해</h2>
숫자가 모든 것을 말해준다: 지난 5년 동안, 글로벌 ETF 시장은 연평균 19%의 견고한 성장률을 기록하며 15조 달러 이상의 운용 자산을 모았다.
1993년 이래로 총 15,866개의 ETF가 생성되었으며, 그 중 2024년에는 1,485개가 새롭게 출시되어 액티브 ETF와 미국 상장 ETF 모두에서 기록을 세웠다.
기관 투자자, 소매 거래자들, 심지어 자금이 부족한 뮤추얼 펀드까지도 유동성, 세금 효율성 및 비용 절감 혜택 때문에 ETF로 몰려들고 있다.
<h2 class="wp-block-heading">액티브 ETF의 부상: 균형 잡기</h2>
ETF는 역사적으로 수동적 전략이 지배해왔지만, 액티브 ETF가 그 존재감을 드러내고 있다. 액티브 펀드는 2024년에 전체 유입의 18%를 차지하여 알파 전략에 대한 수요가 증가하고 있음을 나타냈다.
그럼에도 불구하고 패시브(수동적) 펀드는 여전히 주식 펀드 자산의 50% 이상을 차지하고 있다.
실제로 93%의 ETF가 어떤 종류의 지수를 추적하지만, 액티브 관리의 매력이 혁신을 촉진하고 있다.
패시브 펀드에서 더 적극적인 전략을 찾는 투자자들도 뮤추얼 펀드에서 ETF로의 전환을 촉진하고 있다. 뱅크 오브 아메리카에 따르면, 뮤추얼 펀드가 경쟁력을 유지하기 위해 노력함에 따라 이러한 추세는 향후 몇 년 동안 가속화될 가능성이 높다.
<h2 class="wp-block-heading">SPY 대 VOO: 새로운 ETF 챔피언의 탄생?</h2>
SPDR S&amp;P 500 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)는 1993년 출시 이후로 가장 크고 가장 활발하게 거래되는 ETF로 남아 있다. 그러나 그 왕좌는 도전받고 있다.
Vanguard S&amp;P 500 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>)는 SPY에 비해 6.5베이시스 포인트 낮은 총비용비율을 가지고 있으며, 2026년까지 AUM에서 SPY를 초과할 가능성이 있다.
2024년에는 VOO가 SPY보다 여섯 배 이상의 유입을 기록했다.
<h3 class="wp-block-heading">펀드 흐름: 2024년의 가장 큰 수혜자들</h3>
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>ETF</th>
<th>연초 이후 자금 흐름</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vanguard S&amp;P 500 ETF (VOO)</td>
<td>$122.75 billion</td>
</tr>
<tr>
<td>iShares Core S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVV#NYSE">IVV</a>)</td>
<td>$48.97 billion</td>
</tr>
<tr>
<td>iShares Bitcoin Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NYSE">IBIT</a>)</td>
<td>$37.04 billion</td>
</tr>
<tr>
<td>Vanguard Total Stock Market ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTI#NYSE">VTI</a>)</td>
<td>$29.96 billion</td>
</tr>
<tr>
<td>Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)</td>
<td>$25.38 billion</td>
</tr>
<tr>
<td>iShares Core U.S. Aggregate Bond ETF (AGG)</td>
<td>$20.62 billion</td>
</tr>
<tr>
<td>SPDR Portfolio S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPLG#NYSE">SPLG</a>)</td>
<td>$19.91 billion</td>
</tr>
</tbody>
</table><figcaption class="wp-element-caption">데이터: TradingView 2024년 12월 19일 기준</figcaption></figure>
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/24/12/42594797/trump-wants-to-get-rid-of-the-debt-ceiling-30-year-treasury-bonds-fall-to-2024-lows-stocks-cut-gains">트럼프가 부채 한도를 없애겠다고 나서자: 30년 만기 국채 금리가 2024년 최저치로 하락하고 주식 상승폭이 축소</a></li>
</ul>
사진 출처: Shutterstock.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

연방준비제도(연준)는 다가오는 연방공개시장위원회(FOMC) 회의에서 금리를 인하할 것으로 예상되며, 그 결정은 수요일 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40878710/investors-bet-on-50-basis-point-rate-cut-wall-street-analysts-urge-caution-this-is-">동부 표준시 오후 2시</a>에 발표될 예정이다.
이 중앙은행은 2023년 9월부터 연방기금 금리를 5.25%~5.5%로 유지해 왔으며, 이번 주 금리 인하는 2020년 3월 이후 처음으로 치솟는 인플레이션에 맞서기 위해 시행된 제한적인 통화 정책 기조에서 뚜렷한 전환을 의미한다.
<h3 class="wp-block-heading">금리 인하 기대: 연준은 25 또는 50bp를 선택할 것인가?</h3>
모두가 궁금해하는 핵심 질문은 금리 인하 폭이다. 연준이 신중하게 25bp(베이시스 포인트) 인하를 선택할 것인지, 아니면 이전 금리 인하 사이클의 시작에서처럼 과감하게 50bp 인하를 단행할 것인지가 주목된다.
현재 시장 정서는 월스트리트 경제학자들의 컨센서스와 다르다. CME의 페드워치(FedWatch) 도구에 따르면 트레이더들은 50bp 인하의 가능성을 63%로 가격에 반영하고 있다.
반면 월스트리트 애널리스트들 사이에서는 더 보수적인 25bp 인하에 대한 압도적인 합의가 존재하지만, JP모건 체이스는 50bp 인하를 예측하는 주목할 만한 예외이다.
이 미국 최대 은행에 따르면, 금리는 중립 수준보다 약 150bp 높다. 따라서 매번 회의마다 25bp 인하를 단행하면 정책이 중립적 입장으로 돌아가는 데 거의 1년이 걸린다.
이는 특히 돌이켜보면 7월 시작이 더 적절했을 수 있다는 점을 감안할 때 사이클 시작 시 금리 인하를 우선적으로 적용해야 한다는 주장을 강화한다.
연준이 25bp 또는 50bp 인하를 선택하든, 애널리스트들은 2024년과 2025년까지 일련의 인하가 계속될 것으로 예상하고 있다.
<h3 class="wp-block-heading">금리 인하 이전의 투자자 움직임: 투자자들이 지난주에 가장 많이 구매한 상위 10개 ETF</h3>
이번에 예상되는 금리 인하를 앞두고 투자자들은 포트폴리오를 재편성하여 금리가 낮은 환경에서 혜택을 볼 수 있는 자산으로의 전략적 이동을 나타내는 다양한 상장지수펀드(ETF)에 유입이 크게 발생했다.
이러한 트렌드를 파악하기 위해 벤징가(Benzinga)는 베타파이(VettaFi)의 etfdb.com 데이터를 분석했으며, 투자자들이 가치 중심의 ETF를 선호하는 강한 경향을 보였음을 발견했다.
그 중에서도 iShares MSCI EAFE Value ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFV#NYSE">EFV</a>)와 SPDR Portfolio S&amp;P 500 Value ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPYV#NYSE">SPYV</a>)가 주목받으며, 이는 매크로 환경 변화에 따라 안정성과 방어적 헤지를 제공할 수 있는 자산으로의 선호를 나타낸다.
또한, 전통적인 금리 인하 수혜자인 금도 투자자들의 관심을 끌며, 지난주 동안 가격이 여러 차례 사상 최고가를 기록했고, SPDR Gold Shares(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>)로의 강력한 유입이 이를 뒷받침했다.
기술 섹터, 특히 반도체에 대한 관심도 주목할 만하며, VanEck Semiconductor ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NYSE">SMH</a>)가 상당한 유입을 보였다.
추가적으로, 투자자들은 나스닥 100에 대한 투기적이고 레버리지 전략을 추구했으며, 이는 50bp 인하 가능성이 높아졌다고 해석되었을 가능성이 있다.
투자자들은 ProShares Ultra QQQ(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QLD#NYSE">QLD</a>)와 ProShares UltraPro QQQ(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TQQQ#NYSE">TQQQ</a>)를 구매했다. QLD는 나스닥 100의 일일 성과를 두 배로 제공하고, TQQQ는 세 배로 제공한다.
마지막으로, 인기 있는 소형주 펀드인 iShares Russell 2000 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>)가 5억 달러 이상의 유입을 받아, 투자자들이 차입 비용 감소로 혜택을 받을 것으로 예상되는 소형 국내 기업들에 대한 관심이 높아지고 있음을 나타냈다.
<figure class="wp-block-table is-style-stripes">
<table style="overflow:auto; height: 90px; display: block;">
<thead>
<tr>
<th>ETF 이름</th>
<th>1주일 유입 ($MM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>iShares MSCI EAFE Value ETF</td>
<td>$1,135.48</td>
</tr>
<tr>
<td>SPDR Portfolio S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPLG#NYSE">SPLG</a>)</td>
<td>$820.85</td>
</tr>
<tr>
<td>Vanguard Intermediate-Term Corporate Bond ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VCIT#NYSE">VCIT</a>)</td>
<td>$818.30</td>
</tr>
<tr>
<td>SPDR Portfolio S&amp;P 500 Value ETF</td>
<td>$775.06</td>
</tr>
<tr>
<td>VanEck Semiconductor ETF</td>
<td>$717.11</td>
</tr>
<tr>
<td>Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>)</td>
<td>$698.27</td>
</tr>
<tr>
<td>SPDR Gold Shares</td>
<td>$648.41</td>
</tr>
<tr>
<td>ProShares Ultra QQQ</td>
<td>$646.66</td>
</tr>
<tr>
<td>ProShares UltraPro QQQ</td>
<td>$560.15</td>
</tr>
<tr>
<td>iShares Russell 2000 ETF </td>
<td>$552.24</td>
</tr>
</tbody>
</table>
</figure>
지금 읽기:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40903154/13-etfs-to-own-as-fed-set-to-cut-rates-analysts-highlight-utilities-real-estate-and">금리 인하를 앞두고 꼭 가져야 할 13개 ETF: 애널리스트가 유틸리티, 부동산 등을 강조</a></li>
</ul>
이미지는 Midjourney를 통해 생성된 인공지능 이미지입니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

SPDR Portfolio S&P 500 ETF

뉴스

에 대한 최신 뉴스 SPDR Portfolio S&P 500 ETF (ARCA:SPLG)

목요일, 12월 19, 2024

수요일, 9월 18, 2024

뉴스

파트너 / 기고자

벤징가 글로벌